

ASX RELEASE | OSTEOPORE LIMITED

COLLABORATION AGREEMENT TO DEVELOP ADDITIONAL OSTEOPORE PRODUCT

15 SEPTEMBER 2020: Osteopore Limited (ASX: OSX) (“Osteopore” or the “Company”), a revenue generating medical technology company that has commercialised a range of patented 3D printed bioresorbable products, is pleased to announce that a Research Collaboration Agreement has been signed with the National University of Singapore (NUS) Yong Loo Lin School of Medicine’s Department of Surgery and the National University Hospital (NUH).

This project seeks to investigate the potential for Osteopore’s 3D printed implants to be used in mandibular reconstruction and to gather adequate data for future regulatory submission. The mandible is the largest bone in the human facial skeleton. It holds the lower teeth in place, assists in mastication and forms the lower jawline.

The need for mandibular reconstruction stems from bone loss due to trauma or disease. Currently, widely used solutions include a fibula graft and iliac crest, however both methods can lead to post-surgical complications and donor site morbidities. In Singapore, there are an estimated two to three mandibular reconstructions per week at NUH.

This application of the Osteopore technology would be a further expansion of Osteopore’s ongoing development of oral maxillofacial (OMF) reconstruction solutions. The Osteoplug and Osteomesh is currently approved by the Health Sciences Authority of Singapore for clinical usage in dental reconstruction such as socket preservation and alveolar ridge reconstruction. The Company is progressing into further clinical trials to secure broader regulatory clearances as well as developing second generation material, incorporating additives into the polycaprolactone matrix, to further improve bone regeneration. Successful completion of this research collaboration has the potential to further support OMF product development.

Study Overview

Osteopore, the Department of Surgery at NUS Yong Loo Lin School of Medicine and NUH Department of Surgery will work together on a preliminary in vivo study to determine if the combination of Osteopore’s 3D printed bioresorbable products with bone marrow aspirates (BMA), or similar extracts, could be used to regrow bone following mandibular reconstruction surgery. The distinct and unique advantages of Osteopore’s implants are that they are bioresorbable and can be custom manufactured to fit each patient.

The main objective is to evaluate the effectiveness of Osteopore’s technology for reconstruction of mandibular defects, to provide pre-clinical data for the evaluation of future studies, as well as to support first-in-man studies.

Upon successful completion of this project, the research partners will assess the potential to take the project into targeted in first-in-man studies, followed by Clinical Trials. The completion of human Clinical Trials would be necessary for securing regulatory approval for human application of the technology in future.

Osteopore wishes to advise that this project has a long development pathway and there is no guarantee of Osteopore successfully commercialising the mandible products.

Research Collaboration Agreement

The entire initiative is funded by the National Additive Manufacturing Innovation Cluster (NAMIC), Singapore's national additive manufacturing accelerator. Osteopore will also contribute significant support in the form of guiding the study and data collection methods to ensure alignment to regulatory needs. Following completion of the project, Osteopore shall have a first right to negotiate for a licence to commercialise any project IP developed through the collaboration.

This collaboration structure offers the Company a cost-effective and highly leveraged opportunity to continue to develop the Osteopore technology into new therapeutic applications.

This announcement has been approved for release by the Board of Osteopore.

For more information please contact:

Geoff Pocock

Osteopore Limited

+61 4 1219 4373

geoff_pocock@osteopore.com

About Osteopore Limited

Osteopore Ltd is an Australian and Singapore based medical technology company commercialising a range of bespoke products specifically engineered to facilitate bone healing across multiple therapeutic areas. Osteopore's patented technology fabricates specific micro-structured scaffolds for bone regeneration through 3D printing and bioresorbable material.

Osteopore's patent protected scaffolds are made from proprietary polymer formulations, that naturally dissolve overtime to leave only natural, healthy bone tissue, significantly reducing post-surgery complications that are commonly associated with permanent bone implants.

About NAMIC

The National Additive Manufacturing Innovation Cluster (NAMIC), led by NTUitive, is the national AM accelerator, orchestrating and implementing breakthrough strategies for the future of production harnessing additive manufacturing technologies. Acting as a connector between industry, research performers and public agencies, NAMIC identifies promising AM technologies and companies globally, and funds translational research based on industry sectorial needs and applications. NAMIC also partners with companies to co-create processes, products and solutions, leveraging on its flagship events to create a vibrant AM ecosystem. Together with the agencies, NAMIC has spear-headed AM industrialization efforts through its wide-ranging industry engagements leading to strategic partnerships and projects, growing the AM business community significantly and drawing entrepreneurs to Singapore. Since its inception in October 2015, NAMIC has raised more than \$50 million in private-public funding to support over 200 initiatives covering platform solutions, product development, SkillsFuture initiatives, standards development and certification. More information can be found at <https://namic.sg>